|
Home Ā» Briefs Ā» In Re Androgel Antitrust Litigation

Services

Econ One’s expert economists have experience across a wide variety of services including antitrust, class certification, damages, financial markets and securities, intellectual property, international arbitration, labor and employment, and valuation and financial analysis.

Resources

Econ One’s resources including blogs, cases, news, and more provide a collection of materials from Econ One’s experts.

Cases and Engagements
Get an Inside look at Economics with the experts.
Managing Director
Education

Ph.D. in Economics, University of California, Los Angeles

M.A. in Economics, University of California, Los Angeles

B.S. in Economics, Santa Clara University

Econ One, President, 1997 ā€“ Present

Founded Econ One, 1997

Micronomics, Inc., President and CEO, 1994 ā€“ 1997

Micronomics, Inc., Executive Vice President, 1988 ā€“ 1997

Cofounded Micronomics, Inc., 1988

National Economic Research Associates, Inc. (Last position was Senior Vice President and member of the Board of Directors) 1980 ā€“ 1988

U.S. District Court

U.S. Bankruptcy Court

State Court

Federal Energy Regulatory Commission

Various state tax and regulatory commissions

Private arbitration

International Arbitration

Share this Article
September 25, 2015

In Re Androgel Antitrust Litigation

Econ One was been retained by counsel for the plaintiffs in the case In Re Androgel Antitrust Litigation. The plaintiffs are a class of direct purchasers of the brand name prescription drug AndroGel, a testosterone gel. They allege that the defendant violated antitrust laws by improperly delaying the market entry of cheaper generic substitutes to AndroGel.

Econ One expert Jeffrey Leitzinger submitted an expert report relating to class certification issues. Those issues included the likely impact of a delay in generic competition on the class members, the availability of common, class-wide economic evidence and methodologies that would demonstrate class-wide impact in the form of overcharges, and whether those overcharges could be calculated as a whole on an aggregate basis using reliable methodologies. Dr. Leitzinger also submitted an expert report addressing the issues of monopoly power, market definition, and aggregate overcharge damages. He has provided deposition testimony in this matter.

Industries: Pharmaceutical
Latest Related Resources and Insights